At a cabinet meeting earlier this month, President Trump made an announcement for the pharmaceutical industry.

We're going to give people about a year, a year and a half, to come in, and after that, they're going to be tariffed.

If they have to bring the pharmaceuticals into the country, the drugs and other things, into the country, they're going to be

tariffed at a very, very high rate, like 200%.

Like Trump's tariffs on other industries, a primary goal is to encourage manufacturers to move

their operations into the U.S. And already, some of the largest pharma companies in the world

are responding.

AstraZeneca is expanding its manufacturing capability here in the U.S.,

the UK-based company just announcing a $50 billion expansion.

Drugs giant Roche said Tuesday it would invest $50 billion in the U.S. over the next five years.

Here in this country, it's a $27 billion investment for Eli Lilly and company.

But drug makers from one sector of the industry say that manufacturing in the U.S. isn't really an

option for them.

I spoke to the CEO of one of those companies.

I'm Richard Sano. I'm the CEO of a company called Sandoz.

And it is Sandoz or Sandoz? I feel like I've heard...

People say both.

Yeah.

Sandoz is a Switzerland-based company, and it's one of the world's largest makers of generic drugs.

Generics are medicines whose patents have expired, and can be made by many drug companies,

and they generally cost less than brand-name drugs.

Richard has been in talks with the U.S. government, and he says tariffs aren't the way to

...